Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine

•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunization...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Veterinary immunology and immunopathology 2017-03, Vol.185, p.20-33
Hauptverfasser: Lopera-Madrid, Jaime, Osorio, Jorge E., He, Yongqun, Xiang, Zuoshuang, Adams, L. Garry, Laughlin, Richard C., Mwangi, Waithaka, Subramanya, Sandesh, Neilan, John, Brake, David, Burrage, Thomas G., Brown, William Clay, Clavijo, Alfonso, Bounpheng, Mangkey A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 33
container_issue
container_start_page 20
container_title Veterinary immunology and immunopathology
container_volume 185
creator Lopera-Madrid, Jaime
Osorio, Jorge E.
He, Yongqun
Xiang, Zuoshuang
Adams, L. Garry
Laughlin, Richard C.
Mwangi, Waithaka
Subramanya, Sandesh
Neilan, John
Brake, David
Burrage, Thomas G.
Brown, William Clay
Clavijo, Alfonso
Bounpheng, Mangkey A.
description •Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine. A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine.
doi_str_mv 10.1016/j.vetimm.2017.01.004
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7112906</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165242717300351</els_id><sourcerecordid>2000382846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</originalsourceid><addsrcrecordid>eNqFkcuO1DAQRS0EYnoa_gChLNkk2I6T2Buk1ojHSINY8Nhajl0eqkmcwU6C5gv4bdx0M8AGVparbt16HEKeMFoxytrn-2qFGcex4pR1FWUVpeIe2TDZ1SVvanGfbLKsKbng3Rk5T2lPKW2UlA_JGZdcMKXUhnx_bzzMt4UJrshmS5iuIaDFHJp8MZpxNAOaUFgYhsJBxBXcT_HbyaHH_PlkrMWAptiFLyaaYgU7TzEndj6izaXpGwYoPKwQi7T0S8A5O8yYG6UCT_lH5IE3Q4LHp3dLPr56-eHiTXn17vXlxe6qtEK1cwm8B0U5dN63zDfKdK2qa2hU31vRul5KCsAtdbXvmQLaioblAAhJW1q7tt6SF0ffm6UfwVkIczSDvok4mnirJ4P670zAz_p6WnXHGFf0YPDsZBCnrwukWY-YDtcxAaYlaZ6vXEsuxf-lGRWXUvBMa0vEUWrjlFIEfzcRo_qAW-_1Ebc-4NaU6Yw7lz39c5u7ol98f68L-aYrQtTJIgQLDmPmpN2E_-7wA_9wwT8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1872884225</pqid></control><display><type>article</type><title>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lopera-Madrid, Jaime ; Osorio, Jorge E. ; He, Yongqun ; Xiang, Zuoshuang ; Adams, L. Garry ; Laughlin, Richard C. ; Mwangi, Waithaka ; Subramanya, Sandesh ; Neilan, John ; Brake, David ; Burrage, Thomas G. ; Brown, William Clay ; Clavijo, Alfonso ; Bounpheng, Mangkey A.</creator><creatorcontrib>Lopera-Madrid, Jaime ; Osorio, Jorge E. ; He, Yongqun ; Xiang, Zuoshuang ; Adams, L. Garry ; Laughlin, Richard C. ; Mwangi, Waithaka ; Subramanya, Sandesh ; Neilan, John ; Brake, David ; Burrage, Thomas G. ; Brown, William Clay ; Clavijo, Alfonso ; Bounpheng, Mangkey A.</creatorcontrib><description>•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine. A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine.</description><identifier>ISSN: 0165-2427</identifier><identifier>EISSN: 1873-2534</identifier><identifier>DOI: 10.1016/j.vetimm.2017.01.004</identifier><identifier>PMID: 28241999</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>African swine fever ; African Swine Fever - immunology ; African Swine Fever - prevention &amp; control ; African swine fever virus ; African Swine Fever Virus - genetics ; African Swine Fever Virus - immunology ; Animals ; antibodies ; Antibodies, Viral - blood ; antigens ; Antigens, Viral - genetics ; Antigens, Viral - immunology ; fluorescent antibody technique ; Genetic Vectors ; Genome, Viral ; HEK-293 ; HEK293 Cells ; Humans ; immunization ; Immunogenicity, Vaccine ; interferon-gamma ; kidneys ; macrophages ; Male ; MVA ; Recombinant protein expression ; Reverse vaccinology ; Swine ; T-lymphocytes ; T-Lymphocytes - immunology ; Vaccine development ; Vaccines, Synthetic - genetics ; Vaccines, Synthetic - immunology ; Vaccinia virus ; Vaccinia virus - genetics ; Viral Vaccines - genetics ; Viral Vaccines - immunology</subject><ispartof>Veterinary immunology and immunopathology, 2017-03, Vol.185, p.20-33</ispartof><rights>2017 Elsevier B.V.</rights><rights>Copyright © 2017 Elsevier B.V. All rights reserved.</rights><rights>2017 Elsevier B.V. All rights reserved. 2017 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</citedby><cites>FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165242717300351$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28241999$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lopera-Madrid, Jaime</creatorcontrib><creatorcontrib>Osorio, Jorge E.</creatorcontrib><creatorcontrib>He, Yongqun</creatorcontrib><creatorcontrib>Xiang, Zuoshuang</creatorcontrib><creatorcontrib>Adams, L. Garry</creatorcontrib><creatorcontrib>Laughlin, Richard C.</creatorcontrib><creatorcontrib>Mwangi, Waithaka</creatorcontrib><creatorcontrib>Subramanya, Sandesh</creatorcontrib><creatorcontrib>Neilan, John</creatorcontrib><creatorcontrib>Brake, David</creatorcontrib><creatorcontrib>Burrage, Thomas G.</creatorcontrib><creatorcontrib>Brown, William Clay</creatorcontrib><creatorcontrib>Clavijo, Alfonso</creatorcontrib><creatorcontrib>Bounpheng, Mangkey A.</creatorcontrib><title>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</title><title>Veterinary immunology and immunopathology</title><addtitle>Vet Immunol Immunopathol</addtitle><description>•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine. A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine.</description><subject>African swine fever</subject><subject>African Swine Fever - immunology</subject><subject>African Swine Fever - prevention &amp; control</subject><subject>African swine fever virus</subject><subject>African Swine Fever Virus - genetics</subject><subject>African Swine Fever Virus - immunology</subject><subject>Animals</subject><subject>antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>antigens</subject><subject>Antigens, Viral - genetics</subject><subject>Antigens, Viral - immunology</subject><subject>fluorescent antibody technique</subject><subject>Genetic Vectors</subject><subject>Genome, Viral</subject><subject>HEK-293</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>immunization</subject><subject>Immunogenicity, Vaccine</subject><subject>interferon-gamma</subject><subject>kidneys</subject><subject>macrophages</subject><subject>Male</subject><subject>MVA</subject><subject>Recombinant protein expression</subject><subject>Reverse vaccinology</subject><subject>Swine</subject><subject>T-lymphocytes</subject><subject>T-Lymphocytes - immunology</subject><subject>Vaccine development</subject><subject>Vaccines, Synthetic - genetics</subject><subject>Vaccines, Synthetic - immunology</subject><subject>Vaccinia virus</subject><subject>Vaccinia virus - genetics</subject><subject>Viral Vaccines - genetics</subject><subject>Viral Vaccines - immunology</subject><issn>0165-2427</issn><issn>1873-2534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO1DAQRS0EYnoa_gChLNkk2I6T2Buk1ojHSINY8Nhajl0eqkmcwU6C5gv4bdx0M8AGVparbt16HEKeMFoxytrn-2qFGcex4pR1FWUVpeIe2TDZ1SVvanGfbLKsKbng3Rk5T2lPKW2UlA_JGZdcMKXUhnx_bzzMt4UJrshmS5iuIaDFHJp8MZpxNAOaUFgYhsJBxBXcT_HbyaHH_PlkrMWAptiFLyaaYgU7TzEndj6izaXpGwYoPKwQi7T0S8A5O8yYG6UCT_lH5IE3Q4LHp3dLPr56-eHiTXn17vXlxe6qtEK1cwm8B0U5dN63zDfKdK2qa2hU31vRul5KCsAtdbXvmQLaioblAAhJW1q7tt6SF0ffm6UfwVkIczSDvok4mnirJ4P670zAz_p6WnXHGFf0YPDsZBCnrwukWY-YDtcxAaYlaZ6vXEsuxf-lGRWXUvBMa0vEUWrjlFIEfzcRo_qAW-_1Ebc-4NaU6Yw7lz39c5u7ol98f68L-aYrQtTJIgQLDmPmpN2E_-7wA_9wwT8</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Lopera-Madrid, Jaime</creator><creator>Osorio, Jorge E.</creator><creator>He, Yongqun</creator><creator>Xiang, Zuoshuang</creator><creator>Adams, L. Garry</creator><creator>Laughlin, Richard C.</creator><creator>Mwangi, Waithaka</creator><creator>Subramanya, Sandesh</creator><creator>Neilan, John</creator><creator>Brake, David</creator><creator>Burrage, Thomas G.</creator><creator>Brown, William Clay</creator><creator>Clavijo, Alfonso</creator><creator>Bounpheng, Mangkey A.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20170301</creationdate><title>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</title><author>Lopera-Madrid, Jaime ; Osorio, Jorge E. ; He, Yongqun ; Xiang, Zuoshuang ; Adams, L. Garry ; Laughlin, Richard C. ; Mwangi, Waithaka ; Subramanya, Sandesh ; Neilan, John ; Brake, David ; Burrage, Thomas G. ; Brown, William Clay ; Clavijo, Alfonso ; Bounpheng, Mangkey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c496t-e2be902e7ff61f59a76933e59bbc46db880ee2c0d3fb19e06451ee2e480603d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>African swine fever</topic><topic>African Swine Fever - immunology</topic><topic>African Swine Fever - prevention &amp; control</topic><topic>African swine fever virus</topic><topic>African Swine Fever Virus - genetics</topic><topic>African Swine Fever Virus - immunology</topic><topic>Animals</topic><topic>antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>antigens</topic><topic>Antigens, Viral - genetics</topic><topic>Antigens, Viral - immunology</topic><topic>fluorescent antibody technique</topic><topic>Genetic Vectors</topic><topic>Genome, Viral</topic><topic>HEK-293</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>immunization</topic><topic>Immunogenicity, Vaccine</topic><topic>interferon-gamma</topic><topic>kidneys</topic><topic>macrophages</topic><topic>Male</topic><topic>MVA</topic><topic>Recombinant protein expression</topic><topic>Reverse vaccinology</topic><topic>Swine</topic><topic>T-lymphocytes</topic><topic>T-Lymphocytes - immunology</topic><topic>Vaccine development</topic><topic>Vaccines, Synthetic - genetics</topic><topic>Vaccines, Synthetic - immunology</topic><topic>Vaccinia virus</topic><topic>Vaccinia virus - genetics</topic><topic>Viral Vaccines - genetics</topic><topic>Viral Vaccines - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lopera-Madrid, Jaime</creatorcontrib><creatorcontrib>Osorio, Jorge E.</creatorcontrib><creatorcontrib>He, Yongqun</creatorcontrib><creatorcontrib>Xiang, Zuoshuang</creatorcontrib><creatorcontrib>Adams, L. Garry</creatorcontrib><creatorcontrib>Laughlin, Richard C.</creatorcontrib><creatorcontrib>Mwangi, Waithaka</creatorcontrib><creatorcontrib>Subramanya, Sandesh</creatorcontrib><creatorcontrib>Neilan, John</creatorcontrib><creatorcontrib>Brake, David</creatorcontrib><creatorcontrib>Burrage, Thomas G.</creatorcontrib><creatorcontrib>Brown, William Clay</creatorcontrib><creatorcontrib>Clavijo, Alfonso</creatorcontrib><creatorcontrib>Bounpheng, Mangkey A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary immunology and immunopathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lopera-Madrid, Jaime</au><au>Osorio, Jorge E.</au><au>He, Yongqun</au><au>Xiang, Zuoshuang</au><au>Adams, L. Garry</au><au>Laughlin, Richard C.</au><au>Mwangi, Waithaka</au><au>Subramanya, Sandesh</au><au>Neilan, John</au><au>Brake, David</au><au>Burrage, Thomas G.</au><au>Brown, William Clay</au><au>Clavijo, Alfonso</au><au>Bounpheng, Mangkey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine</atitle><jtitle>Veterinary immunology and immunopathology</jtitle><addtitle>Vet Immunol Immunopathol</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>185</volume><spage>20</spage><epage>33</epage><pages>20-33</pages><issn>0165-2427</issn><eissn>1873-2534</eissn><abstract>•Reverse vaccinology was applied to identify and rank ASFV immunogenic candidates .•Selected ASFV immunogenic candidate proteins were expressed in HEK-293 mammalian cells and MVA constructs .•Immunizations with antigens purified from HEK-293 cells and MVA constructs in swine were safe .•Immunizations with selected antigens induced ASFV-specific antibodies and T-cell responses in swine. A reverse vaccinology system, Vaxign, was used to identify and select a subset of five African Swine Fever (ASF) antigens that were successfully purified from human embryonic kidney 293 (HEK) cells and produced in Modified vaccinia virus Ankara (MVA) viral vectors. Three HEK-purified antigens [B646L (p72), E183L (p54), and O61R (p12)], and three MVA-vectored antigens [B646L, EP153R, and EP402R (CD2v)] were evaluated using a prime-boost immunization regimen swine safety and immunogenicity study. Antibody responses were detected in pigs following prime-boost immunization four weeks apart with the HEK-293-purified p72, p54, and p12 antigens. Notably, sera from the vaccinees were positive by immunofluorescence on ASFV (Georgia 2007/1)-infected primary macrophages. Although MVA-vectored p72, CD2v, and EP153R failed to induce antibody responses, interferon-gamma (IFN-γ+) spot forming cell responses against all three antigens were detected one week post-boost. The highest IFN-γ+ spot forming cell responses were detected against p72 in pigs primed with MVA-p72 and boosted with the recombinant p72. Antigen-specific (p12, p72, CD2v, and EP153R) T-cell proliferative responses were also detected post-boost. Collectively, these results are the first demonstration that ASFV subunit antigens purified from mammalian cells or expressed in MVA vectors are safe and can induce ASFV-specific antibody and T-cell responses following a prime-boost immunization regimen in swine.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>28241999</pmid><doi>10.1016/j.vetimm.2017.01.004</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0165-2427
ispartof Veterinary immunology and immunopathology, 2017-03, Vol.185, p.20-33
issn 0165-2427
1873-2534
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7112906
source MEDLINE; Elsevier ScienceDirect Journals
subjects African swine fever
African Swine Fever - immunology
African Swine Fever - prevention & control
African swine fever virus
African Swine Fever Virus - genetics
African Swine Fever Virus - immunology
Animals
antibodies
Antibodies, Viral - blood
antigens
Antigens, Viral - genetics
Antigens, Viral - immunology
fluorescent antibody technique
Genetic Vectors
Genome, Viral
HEK-293
HEK293 Cells
Humans
immunization
Immunogenicity, Vaccine
interferon-gamma
kidneys
macrophages
Male
MVA
Recombinant protein expression
Reverse vaccinology
Swine
T-lymphocytes
T-Lymphocytes - immunology
Vaccine development
Vaccines, Synthetic - genetics
Vaccines, Synthetic - immunology
Vaccinia virus
Vaccinia virus - genetics
Viral Vaccines - genetics
Viral Vaccines - immunology
title Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A13%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20immunogenicity%20of%20mammalian%20cell%20derived%20and%20Modified%20Vaccinia%20Ankara%20vectored%20African%20swine%20fever%20subunit%20antigens%20in%20swine&rft.jtitle=Veterinary%20immunology%20and%20immunopathology&rft.au=Lopera-Madrid,%20Jaime&rft.date=2017-03-01&rft.volume=185&rft.spage=20&rft.epage=33&rft.pages=20-33&rft.issn=0165-2427&rft.eissn=1873-2534&rft_id=info:doi/10.1016/j.vetimm.2017.01.004&rft_dat=%3Cproquest_pubme%3E2000382846%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1872884225&rft_id=info:pmid/28241999&rft_els_id=S0165242717300351&rfr_iscdi=true